EUVIMEDEUVIMED entdecken
Crossref

Lactobacillus murinus improves liver fibrosis in primary sclerosing cholangitis mice by decreasing taurocholic acid and regulating M2 macrophage polarization

Chenchen Zhang, Zixuan Wang, Dilixiati Kadier, Yu Shen, Zejia Hao, Yutong Zhu, Qian Wu, Lei Li, Ping Jiang

Journal of Biomedical Research · 2026 · 40 · 1

DOI: 10.7555/jbr.40.20260064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Research, 2026. Verfasst von Chenchen Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatic accumulation of bile acids (BAs) contributes to cholestasis-induced liver injury and fibrosis. Our previous studies have shown that Lactobacillus murinus (L. murinus) alleviates liver fibrosis in primary sclerosing cholangitis (PSC) by modulating bile acid metabolism. In this study, we found that L. murinus intervention alleviated hepatic taurocholic acid (TCA) accumulation, cholestasis, and liver fibrosis in PSC mice. TCA was shown to promote liver fibrosis in PSC mice by enhancing M2 macrophage-mediated secretion of transforming growth factor beta 1 (TGF-β1). Macrophage depletion in PSC mice reduced the proportion of M2 macrophages and TGF-β1 cytokine levels, alleviating liver fibrosis. L. murinus exhibited bile salt hydrolase (BSH) activity, preferentially hydrolyzing glycine-conjugated bile acids. Furthermore, L. murinus reduced TCA reabsorption into the portal circulation by suppressing farnesoid X receptor (Fxr) gene expression in the ileum, thereby alleviating hepatic TCA accumulation and mitigating liver fibrosis in PSC mice. These findings suggest that L. murinus mitigates PSC-associated liver fibrosis, which is associated with reduced TCA levels and regulation of M2 macrophage polarization, offering a potential therapeutic strategy for PSC.

Schlagwörter

Stichwörter der Autor:innen

Lactobacillus murinusPSCTCAliver fibrosismacrophage polarization

Autor:innen und Institutionen

  • Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
  • The Key Lab of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.

Zitieren

APA

Zhang, C., Wang, Z., Kadier, D., Shen, Y., Hao, Z., Zhu, Y., Wu, Q., Li, L., & Jiang, P. (2026). Lactobacillus murinus improves liver fibrosis in primary sclerosing cholangitis mice by decreasing taurocholic acid and regulating M2 macrophage polarization. Journal of Biomedical Research, 40, 1. https://doi.org/10.7555/jbr.40.20260064

Vancouver

Zhang C, Wang Z, Kadier D, Shen Y, Hao Z, Zhu Y, et al. Lactobacillus murinus improves liver fibrosis in primary sclerosing cholangitis mice by decreasing taurocholic acid and regulating M2 macrophage polarization. Journal of Biomedical Research. 2026;40:1. doi:10.7555/jbr.40.20260064

BibTeX
@article{Zhang2026,
  author = {Zhang, Chenchen and Wang, Zixuan and Kadier, Dilixiati and Shen, Yu and Hao, Zejia and Zhu, Yutong and Wu, Qian and Li, Lei and Jiang, Ping},
  title = {Lactobacillus murinus improves liver fibrosis in primary sclerosing cholangitis mice by decreasing taurocholic acid and regulating M2 macrophage polarization},
  journal = {Journal of Biomedical Research},
  year = {2026},
  volume = {40},
  pages = {1},
  doi = {10.7555/jbr.40.20260064}
}
Kostenlos starten →